Adverum Biotechnologies, Inc.(ADVM)Earnings, Financials & Key Ratios
ADVM•NASDAQ
$4.36
Price updated Jun 20, 2026
AboutAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Show more
- Revenue$1M-72.2%
- EBITDA-$136M-9.9%
- Net Income-$131M-7.2%
- EPS (Diluted)-6.62-227.7%
- Gross Margin100%
- EBITDA Margin-13550.6%-295.6%
- Operating Margin-13915.9%-288.5%
- Net Margin-13092.7%-286.0%
- ROE-189.84%-93.3%
ADVM Price & Volume
Adverum Biotechnologies, Inc. (ADVM) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Corporate Solvency
Investment Thesis • Updated 2025Q3
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding insolvency
Key Thesis Takeaways
- Adverum Biotechnologies faces a precarious financial outlook as it continues to prioritize high-cost clinical development programs despite a complete absence of recurring revenue.
- The company's rapid erosion of equity to a $55.7M deficit and a deteriorating current ratio of 0.65 suggest an urgent need for dilutive financing or strategic partnerships.
- Investors should monitor the company's ability to manage its $88.9M debt load against a shrinking cash base of $26.1M to avoid a potential liquidity crisis.
Verdict Logic
Negative: The company's current ratio of 0.65 and the rapid depletion of cash to $26.1M indicate a high risk of insolvency and significant shareholder dilution in the near term.
ADVM Growth Metrics
Adverum Biotechnologies, Inc. (ADVM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.75%
5 Years31.95%
3 Years-48.91%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-88.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-109.27%
Return on Capital
10 Years-44.42%
5 Years-54.32%
3 Years-67.64%
Last Year-95.08%
Peers Comparison
Key metrics vs top competitors for Adverum Biotechnologies, Inc. (ADVM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.36 | $96.26M | -0.66 | -72.22% | -13092.7% | -189.84% | — | |
| $1.49 | $504.4M | -6.48 | 8.83% | -1605.22% | -127987.5% | — | |
| $3.65 | $357.36M | -2.03 | 25.39% | -281.59% | -677.39% | — | |
| $374.68 | $11.05B | 54.78 | 33.94% | 53.92% | 19.25% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $58.79 | $11.31B | 32.66 | 12.87% | 8.29% | 4.41% | — |
Compare ADVM vs Peers
Adverum Biotechnologies, Inc. (ADVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ADVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADVM Frequently Asked Questions
Adverum Biotechnologies, Inc. (ADVM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Adverum Biotechnologies, Inc.'s revenue?
Adverum Biotechnologies, Inc. (ADVM) reported $1.0M in revenue for fiscal year 2024. This represents a 3233% increase from $0.0M in 2012.
How fast is Adverum Biotechnologies, Inc. growing?
Adverum Biotechnologies, Inc. (ADVM) saw revenue decline by 72.2% over the past year.
Is ADVM profitable?
Adverum Biotechnologies, Inc. (ADVM) reported a net loss of $204.4M for fiscal year 2024.
Dividend & Returns
What is ADVM's return on equity?
Adverum Biotechnologies, Inc. (ADVM) has a return on equity (ROE) of -189.8%. Negative ROE indicates the company is unprofitable.
What is Adverum Biotechnologies, Inc.'s free cash flow?
Adverum Biotechnologies, Inc. (ADVM) had negative free cash flow of $138.4M in fiscal year 2024, likely due to heavy capital investments.